Auxilium Pharmaceuticals, Inc.

Type: Public
On the web: http://www.auxilium.com

Auxilium Pharmaceuticals is supplementing men's manliness. The company is focused on developing treatments for urological and sexual health. Auxilium's lone marketed product is Testim, a transdermal gel testosterone replacement treatment for hypogonadism (low or decreased testosterone production). To increase Testim's market penetration, Auxilium has entered into partnerships to disseminate its product abroad. Paladin Labs will market Testim in Canada, while Ipsen is marketing it in Europe. DPT Laboratories manufactures Testim for Auxilium which is also researching drugs for other conditions related to scarring and pain.

Key numbers for fiscal year ending December, 2007:
Sales: $95.7M
One year growth: 39.8%
Net income: ($40.7)M

Officers:
Chairman: Rolf A. Classon
President, CEO, and Director: Armando Anido
CFO: James E. (Jim) Fickenscher

Competitors:
Par Pharmaceutical Companies
Solvay
Watson Pharmaceuticals